Loading
Latest filing published 30 Jul 2025 for Lexaria Bioscience Corp., €4,319.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John Martin Docherty discloses dealings in 2 companies, chiefly Lexaria Bioscience Corp. and Lexaria Corp. Between 15 May 2015 and 29 July 2025, the trades on record add up to 13 filings.
No open-market sale appears; the market trades are 5 purchases worth €188k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 7 share grants. So far in 2025, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €19k.
The record was last updated on 30 July 2025 with an open-market purchase (€4,319) in Lexaria Bioscience Corp. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations